New pill aims to slow vision loss in dry AMD
NCT ID NCT05170048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The goal is to see if EG-301 can safely slow vision loss and reduce damage to the retina.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.